ETF Evaluator:
REX Peptide ETF ()
Follow This ETF
(as of Nov 13)
Best Performing in Health Over the Last Year
| 69.8% | iShares Genomics Immnlgy & Hlthcr ETF (IDNA) |
| 65.1% | ARK Genomic Revolution ETF (ARKG) |
| 55.0% | Global X Genomics & Biotechnology ETF (GNOM) |
| 47.7% | First Trust Nasdaq Pharmaceuticals ETF (FTXH) |
| 46.3% | WisdomTree BioRevolution ETF (WDNA) |
Risk
Index
Risk
Index
ETF Details
REX Peptide ETF Overview
REX Peptide ETF (PEPT) is a passively managed Sector Equity Health exchange-traded fund (ETF). Rex launched the ETF in 2026.
The investment seeks investment results that correspond generally to the price and yield (before the fund’s fees and expenses) of an index comprised of companies in the peptides industry.
It tracks the investment results, before fees and expenses, of the VettaFi Peptide Index℠ (the “Index”), which is designed to track the performance of equity securities of companies that are strategically positioned to advance the development, manufacturing, and commercial adoption of peptide-based products—including therapeutics, supplements, cosmetics, and medical devices—along with the enabling technologies essential for peptides. The fund is non-diversified.
About REX Peptide ETF (PEPT)
There are 1 members of the management team with an average tenure of 0.05 years: Matthew Holcomb (2026). Management tenure is more important for actively managed ETFs than passive index ETFs.
The ETF has 1 primary benchmark: VettaFi Peptide TR USD index with a weighting of 100%. REX Peptide ETF has 35 securities in its portfolio. The top 10 holdings constitute 71.7% of the ETF’s assets. The ETF meets the SEC requirement of being classified as a nondiversified fund. The ETF is not considered to have an ESG focus with its investment selection and management.
REX Peptide ETF is part of the Equity global asset class and is within the Sector Equity ETF group. REX Peptide ETF has 29.6% of its portfolio invested in foreign issues. The overall assets allocated to domestic stock is 70.0% There is 29.6% allocated to foreign stock, and 0.0% is allocated to preferred stocks. The bond allocation as a percentage of total assets is 0.0% (0.0% domestic bond, 0.0% foreign bond and 0.0% convertible bond). REX Peptide ETF has 0.4% of the portfolio in cash.
Assets Under Management
The fund has $1 million in total assets, which is below the $2 billion average for the Health category. Normally, lower assets under management translates to higher average expense ratios, and greater total assets are desired. However, for some investment categories, such as small-cap investing, it may be difficult for the manager to fully employ the desired active strategy if assets grow too large or too quickly.
PEPT Performance and Fees
The expense ratio measures how much of a fund’s assets are used for administrative expenses and operating expenses, including adviser fees and fees for the transfer agent and custodial services. The REX Peptide ETF expense ratio is above average compared to funds in the Health category. REX Peptide ETF has an expense ratio of 0.65%, which is 25% higher than its category average, making the fund expense ratio grade a D. While it is difficult to predict returns, it is known that high annual expense ratios reduce your rate of return, and excessive fees are difficult to overcome. Active management normally comes with higher expense ratios than passive index management. Certain investment categories such as small company and foreign also normally have higher expense ratios. It is best to compare fund expense ratios against the category averages for meaningful assessments.
High portfolio turnover can translate to higher expenses and lower aftertax returns. REX Peptide ETF has a portfolio turnover rate of 0%, which indicates that it holds its assets around /years. By way of comparison, the average portfolio turnover is 49% for the Health category.
Recently, in the month of October 2026, REX Peptide ETF returned 0.0%, which earned it a grade of NA, as the Health category had an average return of 3.6%. The letter grades of A, B, C, D and F are based upon relative rankings within the investment category. A grade of A, for example, would indicate that the return is in the highest 20% for that time period compared to all ETFs in that category.
REX Peptide ETF has a trailing yield of 0.00%, which is below the 1.14% category average.
The fund normally distributes its income quarterly and its capital gains annually.
It’s natural to seek the best-performing investments, but you must consider the relationship between risk and return and the impact of costs and taxes on your realized returns.
For more ETF grades, analysis and screening tools to help your investment discovery, join AAII for a $2, full-access trial. Learn more here: https://invest.aaii.com/membership.
Otherwise, for more information about REX Peptide ETF, including its riskiness, submit your email to unlock the rest of the article.
Gain access to exclusive AAII member-only content.
PEPT Trailing NAV Total Returns Data as of 10/31/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| PEPT Return (NAV) | na | na | na | na | na | na |
| PEPT Return (Price) | na | na | na | na | na | na |
| NAV +/- Price Return | na | na | na | na | na | na |
| Health Avg | 3.6% | 9.6% | 27.6% | 21.0% | 4.1% | 10.8% |
| PEPT Grade (NAV) | na | na | na | na | na | na |
| +/- Category (NAV) | na | na | na | na | na | na |
| PEPT Tax-Cost Ratio | na | na | na | na | na | na |
PEPT Annual NAV Total ReturnsData as of 10/31/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| PEPT Return (NAV) | na | na | na | na | na | na | na | na | na | na | na |
| PEPT Return (Price) | na | na | na | na | na | na | na | na | na | na | na |
| NAV +/- Price Ret | na | na | na | na | na | na | na | na | na | na | na |
| Health Avg | 20.3% | 21.8% | 0.1% | 2.2% | -16.3% | 4.3% | 30.5% | 25.4% | -1.5% | 26.5% | -10.2% |
| PEPT Grade (NAV) | na | na | na | na | na | na | na | na | na | na | na |
| +/- Category | na | na | na | na | na | na | na | na | na | na | na |
| Risk Measures | |
| Beta: | na |
| R-Squared: | na |
| Standard Deviation: | na |
| Category Risk Index: | na |
| Category Risk Rating: | |
| Total Risk Index: | na |
| Total Risk Rating: | |
| Portfolio Characteristics | |
| Yield: | -- |
| Total Assets: | $ 2 Mil |
| Share Class Assets: | $ 2 Mil |
| Turnover: | na |
| Expense Ratio: | 0.65% |
| Index Fund: | Yes |
| Index Tracked: | VettaFi Peptide TR USD |
| Index Weighting: | 100% |
| Leveraged: | No |
| Socially Responsible Fund: | No |
| Capital Gains Distribution Frequency: | Annually |
| Income Distribution Frequency: | Quarterly |
Management Team
| Number of Managers: 1 | |||
| Longest Tenure: 0.1 years | |||
| Average Tenure: 0.1 years | |||
| Managers (Year): Holcomb Matthew (2026) | |||
Portfolio Composition (as of 10/30/26)
| # of Holdings: | 35 |
| % in Top 10 Holdings: | 71.7% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 29.6% |
Portfolio Allocation |
|
| Domestic Stock: | 70.0% |
| Foreign Stock: | 29.6% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | -0.0% |
| Cash: | 0.4% |
Purchase Information
| Legal Structure: | Open Ended Investment Company |
| Fund Family: | Rex |
| Phone Number: | 800-617-0004 |
| Website: | |
| Inception Date: | October 13, 2026 |
Expenses and Fees
| Expense Ratio (%): | 0.65% (Rating: Above Avg) |
| Category Average Expense Ratio (%): | 0.52% |
